The clinical utility of pharmacogenomic testing in haematology patients with invasive fungal disease (IFD) receiving azole therapy has not been defined. We report our experience with CYP2C19 testing in haematological patients requiring voriconazole therapy for IFD.
Introduction
Despite interpatient variability in voriconazole metabolism attributable to cytochrome P450 (CYP450) polymorphisms (particularly CYP2C19), the role of pharmacogenomic testing to support the management of invasive fungal disease (IFD) is undefined. Polymorphisms in the CYP2C19 gene result in subpopulations of patients with differing rates of non-linear voriconazole clearance, spanning ultrarapid to poor.
1,2 Genetic polymorphism of CYP2C19 accounts for nearly 50% variance in voriconazole clearance, whilst serum levels in poor metabolizers (PMs) can be four to five times higher than in extensive metabolizers (EMs).
3,4 The ability to predict the need for variations in voriconazole dosing at the commencement of therapy would mitigate risks of toxicity and subtherapeutic dosing in high-risk populations, highlighting the potential utility of CYP2C19 genotyping for optimizing in vivo voriconazole dosing. 5 The utility of pharmacogenomic testing outside healthy volunteers and in 'real-life' cohorts of haematology patients receiving treatment dose voriconazole for IFD has not been well defined.
We explored the use of CYP2C19 genotyping in a cohort of patients with haematological malignancy requiring voriconazole treatment for IFD. We aimed to report the allelic frequencies of CYP2C19 in this cohort and demonstrate the effects on voriconazole exposure, reported toxicities and patient outcome according to genotype.
Methods
A review of a prospectively collected single-centre CYP2C19 genotypic testing in patients with an IFD on voriconazole therapy was undertaken at Peter MacCallum Cancer Centre (PMCC). PMCC is a tertiary referral centre with a large haematology service (although it does not perform allogeneic stem cell transplantation). As a pilot study, 19 consecutive patients with a haematological malignancy receiving presumptive or definitive voriconazole therapy underwent CYP2C19 testing from 2013 to 2014. 
CYP2C19 testing
CYP2C19 testing was performed on patient whole blood or via buccal cells (mouth swab) using PCR and RFLP analysis for the common CYP2C19 gene polymorphisms/mutations (alleles: *1, *2, *3 and *17). CYP2C19 testing was performed in real time and did not inform initial voriconazole therapy.
Voriconazole dosing and levels
Voriconazole dispensing data were obtained from pharmacy records. All voriconazole levels were determined via a validated HPLC assay at an accredited centre, using methods previously described.
6 Reported toxicities were obtained from routine clinical reviews and medical records. Clinical outcome, voriconazole treatment duration and mortality data (30 and 60 day) were recorded. According to PMCC guidelines, the voriconazole loading dosing was 6 mg/kg twice daily (intravenous) for ≥24 h, followed by 4 mg/kg twice-daily maintenance dosing thereafter (oral administration preferred). Following initial 4 mg/kg maintenance dosing, subsequent dosing adjustments were made by the treating clinician based on voriconazole levels. Voriconazole levels were determined as morning trough levels, with frequency determined by the treating clinician. Therapeutic voriconazole exposure was defined as 1 -5.5 mg/L for the purposes of analysis.
Definitions
IFD was defined as possible, probable or proven, according to EORTC criteria.
7 CYP2C19 genotypes and phenotypes were classified according to the following criteria: CYP2C19*17/*17, ultrarapid metabolizer (UM); CYP2C19*17/*1, heterozygote ultrarapid metabolizer (HUM); CYP2C19*1/*1, EM; CYP2C19*17/2 or 3, intermediate metabolizer (IM); CYP2C19*1/2 or 3, IM; and CYP2C19*2 or 3/*2 or 3, PM.
Ethics review
The study was reviewed and approved by the PMCC human research ethics committee. Informed consent was obtained from study participants prior to CYP2C19 testing.
Results
Patient characteristics are summarized in Table 1 , demonstrating a male predominance (12/19, 63%) and a median age of 64 years. The WT CYP2C19*1/*1 (EM) phenotype was the most prevalent (8/19, 42%). Twenty-six percent (5/19) contained a PM allele (*2/*3), generating an IM phenotype. No patients were homozygous for *2 or *3. The median time to CYP2C19 testing result was 11 days (range 3 -26 days). The median number of voriconazole levels per patient was three, the number of voriconazole levels for each CYP2C19 phenotype(s) is highlighted in Table 2 .
The relationship between CYP2C19 genotype/phenotype and voriconazole exposure/toxicity is summarized in Table 2 . The highest first trough voriconazole levels (median 4.8 mg/L) were achieved in the IM group and the lowest in the UM/HUM group (median 2.2 mg/L). The median voriconazole levels for IM, EM and HUM/UM patients were 5.23, 3.3 and 1.25 mg/L, respectively. Only one HUM/UM patient (1/6, 16%) had levels .1 mg/L for their entire 61 day treatment course. The highest rates of clinical toxicity were seen in the IM group (3/5, 60%). The median number of dose adjustments before achieving therapeutic voriconazole exposure was also highest in the IM group (Table 2) . Only patients in the EM or UM/HUM returned a therapeutic level ,1 mg/L at some stage of therapy and 3/7 (42%) of these patients were coadministered a CYP2C19 inhibitor (cimetidine or omeprazole) to increase voriconazole levels.
Discussion
IFD remains a major cause of morbidity and mortality in haematology patients. 8 Delivering voriconazole treatment at optimal therapeutic levels and without toxicity is essential to improving outcomes. 9 Our pilot study of pharmacogenomic testing in patients receiving voriconazole for an IFD demonstrates that CYP2C19 genotyping is feasible and may predict patients at risk of voriconazole toxicity and variation in levels.
Current antifungal treatment guidelines do not support routine use of pharmacogenomic testing due to paucity of in vivo controlled studies. 10 Our results highlight the utility of CYP2C19 genotyping for predicting undesirable levels or toxicity in ethnic-risk groups with a higher proportion of IM and PM phenotypes (Caucasians, 10%-23% IM; Asians, 13%-23% PM). 11 Genotyping may also indicate why some patients fail to achieve therapeutic levels despite absence of underabsorption or drug -drug interactions, thereby facilitating timely initiation of CYP2C19 inhibition or aggressive voriconazole dosing for patients with HUM or UM phenotypes. Reducing time to therapeutic voriconazole exposure supports strategies to optimize delivery and time to adequate antifungal therapy for improved IFD outcomes. 12 Few studies have examined the use of the pharmacogenomics in the management of IFD in adult haematology patients. Healthy volunteer and mixed patient population studies have demonstrated variations in serum voriconazole levels due CYP2C19 polymorphisms. However, these may not apply to ethnically diverse populations. 3, 13, 14 Small pilot studies in cystic fibrosis and stem cell transplant patients demonstrated IM patients take longer to achieve therapeutic levels with reduced overall voriconazole clearance, similar to our findings. 15, 16 Hicks et al. 17 demonstrated that CYP2C19*17 (HUM/UM) was associated with subtherapeutic levels in immunosuppressed paediatric patients and suggested consideration of genotype-based dosing. A recent prospective study assessed voriconazole levels/toxicity and CYP2C19 genotypes, demonstrating that PM had higher average voriconazole levels. Contrary to our experience, this study included predominately patients with non-haematological malignancy receiving voriconazole for prophylaxis or empirical therapy. 18 Despite limitations of small study numbers and clinicians not being blinded to the CYP2C19 genotype, our findings represent the real-life experience of voriconazole dosing and pharmacogenetic evaluation in haematology patients receiving treatmentdose triazole therapy. We demonstrated that initial voriconazole levels based on standardized dosing/kg correlated well with CYP2C19 genotype/phenotype. Toxicity requiring dose reduction only occurred in patients with the IM phenotype. Higher Trubiano et al. Pharmacogenomics, invasive fungal infections and voriconazole therapy voriconazole levels and toxicity occurred in IM patients even considering more concurrent steroid use, a known cause of reduced voriconazole concentrations. 19 Our experience supports the role of pharmacogenomics in azole therapy. Furthermore, the cost of the CYP2C19 genotyping (AUD 90) was not prohibitive.
We demonstrated in a single-centre study of haematology patients that voriconazole exposure and toxicity was highest for IM and lowest for HUM/UM phenotypes. Time to therapeutic voriconazole levels was longer in the IM group, whilst refractory subtherapeutic levels requiring CYP2C19 inhibition were only seen in the EM, HUM and UM phenotypes. The benefit of CYP2C19 genotyping may lie in predicting the 'extremes': (i) those likely to have supratherapeutic levels and toxicity; and (ii) those likely to have subtherapeutic levels (who may benefit from CYP2C19). Prospective studies are required to evaluate the utility of CYP2C19 genotyping with companion voriconazole dosetitrating algorithms and toxicity risk prediction models.
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